Related Experiment Video
Updated: Feb 23, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Binimetinib for the treatment of NRAS-mutant melanoma
Paola Queirolo1, Francesco Spagnolo1
1a Department of Medical Oncology , Ospedale Policlinico San Martino , Genova , Italy.
Introduction:
Activating NRAS mutations occur in approximately 15-20% of melanomas and are the second most common oncogenic driver mutation in this disease, after BRAF mutations. There is an unmet medical need for new targeted therapy opportunities in metastatic patients whose tumors harbor an NRAS mutation. Binimetinib, a mitogen-activated protein kinase kinase (MEK) inhibitor, has shown clinical activity in this group of patients. Areas covered: The purpose of this paper was to review the safety, activity and efficacy of the MEK inhibitor binimetinib for the treatment of NRAS-mutant melanoma, as well as to discuss future therapeutic perspectives such as multiple pathways, targeted therapy, and combinations with immunotherapy. Expert commentary: Only a modest progression-free survival (PFS) benefit was observed in NRAS-mutated patients who received binimetinib compared with dacarbazine in a randomized phase 3 clinical trial, with no improvement in overall survival. Nevertheless, binimetinib represents another promising treatment option for advanced melanoma and the first molecularly targeted therapy for the NRAS-mutant population. Binimetinib may also have a role in treating NRAS-mutated melanoma patients after failure of immunotherapy.
Insights
Binimetinib, a MEK inhibitor, shows clinical activity in NRAS-mutant melanoma, offering a new targeted therapy. While it provided a modest progression-free survival benefit, further research into combination therapies is warranted.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Activating NRAS mutations are common in melanoma, driving significant unmet needs for targeted therapies.
- Binimetinib is a mitogen-activated protein kinase kinase (MEK) inhibitor investigated for NRAS-mutant melanoma.
- BRAF mutations are the most common oncogenic drivers in melanoma, followed by NRAS mutations.
Purpose of the Study:
- To review the safety, activity, and efficacy of binimetinib in NRAS-mutant melanoma.
- To discuss future therapeutic perspectives, including combination therapies and immunotherapy.
- To evaluate binimetinib as a targeted therapy for metastatic melanoma with NRAS mutations.
Main Methods:
- Review of clinical trial data for binimetinib in NRAS-mutant melanoma.
- Analysis of safety and efficacy outcomes, including progression-free survival and overall survival.
- Discussion of future treatment strategies and combination approaches.
Main Results:
- Binimetinib demonstrated clinical activity in patients with NRAS-mutant melanoma.
- A randomized phase 3 trial showed a modest progression-free survival benefit for binimetinib over dacarbazine.
- No significant improvement in overall survival was observed in the trial.
Conclusions:
- Binimetinib is a promising targeted therapy option for advanced NRAS-mutant melanoma.
- It represents the first molecularly targeted therapy specifically for the NRAS-mutant population.
- Binimetinib may be considered for patients who have progressed after immunotherapy.
More Related Videos
06:09Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
